Contrive Datum Insights has published "Genomics Services Market Size, Share & Industry Analysis, By Service type (Next-Generation Sequencing Services, Sanger Sequencing Services, Microarray Services, Genotyping Services, Epigenomics Services, Bioinformatics and Data Analysis Services, Other Genomics Services), Sequencing technology (Short-Read Sequencing, Long-Read Sequencing, Sanger Sequencing, Microarray-Based Platforms, Real-Time PCR and Digital PCR), Application (Research, Clinical Diagnostics, Drug Discovery and Development, Precision and Personalized Medicine, Agriculture and Animal Genomics, Consumer Genomics), Workflow stage (Sample Preparation and Library Construction, Sequencing / Data Generation, Primary and Secondary Analysis, Tertiary Analysis and Interpretation, Reporting and Data Management), End user (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Hospitals and Diagnostic Laboratories, Government and Public Health Agencies, Agricultural and Food Companies, Direct-to-Consumer), Sample type (Blood, Tissue, Saliva and Buccal Swab, Microbial and Environmental Samples, Plant and Animal Samples, Other Sample Types), Disease area (Oncology, Rare and Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Other Disease Areas), Service provider model (Core Facility and Academic Service Labs, Commercial Genomics Service Providers, Instrument Vendor Service Divisions, Clinical Reference Laboratories, Contract Research Organization Genomics Units), Project scale (Single-Sample and Small-Batch Projects, Mid-Scale Cohort Studies, Population-Scale and Biobank Programs, Ongoing Routine Testing Volumes), Delivery model (Outsourced Service Contracts, Fee-for-Service Per Sample, Subscription and Bundled Analysis Plans, Partnership and Collaborative Programs), Regulatory and accreditation status (Research Use Only, CLIA / CAP Certified Clinical, ISO 15189 Accredited, CE-IVD / FDA-Cleared or Approved Assays), and Regional Forecast, 2026-2034". The study sizes the global genomics services market at USD 14 billion in 2025 and projects growth from USD 15.75 billion in 2026 to USD 36.6 billion by 2034, a compound annual growth rate of 11.12% across the forecast period.
Genomics services are contract and outsourced offerings that generate and interpret DNA and RNA data for a customer, covering sample preparation, sequencing, genotyping, epigenomic profiling and bioinformatic analysis. They are delivered by commercial laboratories, clinical reference laboratories, academic core facilities and the service arms of instrument makers, usually priced per sample or per project. Buyers include academic institutes, pharmaceutical and biotechnology companies, contract research organizations, hospitals, public health agencies, agricultural firms and consumers.
Falling cost per genome and rising sequencing throughput
Falling cost per genome and rising sequencing throughput is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 11.12% a year, the service type lines exposed to it move fastest: Epigenomics Services compounds at 15.29%, taking its share of revenue from 5% to 7% and its value from USD 0.7 billion to USD 2.56 billion.
Where the forecast could be beaten: sequencing prices fall faster and unlock larger volumes, reimbursement for genomic tests broadens, and national genome programs outsource more work to commercial providers. The study puts that case at USD 42 billion in 2034, against USD 36.6 billion in the base.
Against that, reimbursement stalls, data localisation rules push work in-house or in-region, and academic funding stays weak, so volume growth slows and prices fall faster than volumes rise. On that reading 2034 revenue stops at USD 29.5 billion. The weight of the problem sits in Microarray Services: 9% of 2025 revenue growing at 3.88%, well under the market's 11.12%.
Next-Generation Sequencing Services Scale Against Epigenomics Services Momentum
Two positions matter, and they are set by service type. Next-Generation Sequencing Services carries 46% of 2025 revenue (USD 6.44 billion) and is still the largest line in 2034 at 50%, hard to take from an incumbent. Epigenomics Services, at 15.29%, is where the USD 14 billion base is redistributed. The two demand different capabilities.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Service type | Next-Generation Sequencing Services | 46% · USD 6.44 billion | — |
| Sequencing technology | Short-Read Sequencing | 58% · USD 8.12 billion | Long-Read Sequencing 20.18% |
| Application | Clinical Diagnostics | 32% · USD 4.48 billion | Precision and Personalized Medicine 17.77% |
| Workflow stage | Sequencing / Data Generation | 40% · USD 5.6 billion | Tertiary Analysis and Interpretation 15.51% |
| End user | Hospitals and Diagnostic Laboratories | 28% · USD 3.92 billion | Direct-to-Consumer 14.06% |
| Sample type | Blood | 52% · USD 7.28 billion | Microbial and Environmental Samples 14.06% |
| Disease area | Oncology | 34% · USD 4.76 billion | Neurological Disorders 12.72% |
| Service provider model | Commercial Genomics Service Providers | 38% · USD 5.32 billion | Clinical Reference Laboratories 13.83% |
| Project scale | Single-Sample and Small-Batch Projects | 30% · USD 4.2 billion | Population-Scale and Biobank Programs 15.77% |
| Delivery model | Fee-for-Service Per Sample | 42% · USD 5.88 billion | Subscription and Bundled Analysis Plans 16.4% |
| Regulatory and accreditation status | Research Use Only | 46% · USD 6.44 billion | CE-IVD / FDA-Cleared or Approved Assays 13.54% |
- Based on regional analysis, North America led the global genomics services market in 2025 with 41% of global revenue at USD 5.74 billion, reaching USD 13.18 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 24% in 2025 to 31% in 2034, with revenue growing from USD 3.36 billion to USD 11.35 billion.
- Middle East and Africa remains the smallest region throughout, at 3% of 2025 revenue and 3% by 2034.
- Epigenomics Services is projected to grow at 15.29% over the forecast period, the fastest of any service type line.
- The United States is the largest single country market at USD 5.14 billion in 2025, 36.71% of global revenue.
The report segments the market across eleven axes; by service type, and by sequencing technology, application, workflow stage, end user, sample type, disease area, service provider model, project scale, delivery model and regulatory and accreditation status; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 29.5 billion and USD 42 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.